Organizing Committee
Member
David Santamaría (Organising Comittee)
David Santamaría

Leads the Novel Ras regulators in cancer & homeostasis group at Centro de Investigación del Cáncer (CIC) in Salamanca.

Organising comittee signature

Organizing Committee member

David Santamaría received his PhD from University Autónoma of Madrid (Spain) in 1999, under the guidance of Prof. Jorge B. Schwartzman, studying replication fork barriers. He then joined the laboratory of Prof. Ronald A. Laskey, (1999-2003) at the Wellcome/CRC Institute (Cambridge, UK) where he dealt with the initiation of DNA replication and its connection with cell cycle control. He returned to Spain (2003-2016) as a staff scientist in Prof. Mariano Barbacid group (CNIO, Madrid) where he used mouse genetics to conduct a comprehensive analysis of the Cyclin Dependent Kinase family and to identify therapeutic targets in lung adenocarcinoma. He joined the European Institute of Chemistry and Biology (IECB, Bordeaux, France) as an independent group leader in 2016 and obtained a DR2 INSERM position starting January 2018. Since December 2021 he is a member of the CIC faculty.

David Santamaría

Leads the Novel Ras regulators in cancer & homeostasis group at Centro de Investigación del Cáncer (CIC) in Salamanca.

Organising comittee signature

Organizing Committee member

David Santamaría received his PhD from University Autónoma of Madrid (Spain) in 1999, under the guidance of Prof. Jorge B. Schwartzman, studying replication fork barriers. He then joined the laboratory of Prof. Ronald A. Laskey, (1999-2003) at the Wellcome/CRC Institute (Cambridge, UK) where he dealt with the initiation of DNA replication and its connection with cell cycle control. He returned to Spain (2003-2016) as a staff scientist in Prof. Mariano Barbacid group (CNIO, Madrid) where he used mouse genetics to conduct a comprehensive analysis of the Cyclin Dependent Kinase family and to identify therapeutic targets in lung adenocarcinoma. He joined the European Institute of Chemistry and Biology (IECB, Bordeaux, France) as an independent group leader in 2016 and obtained a DR2 INSERM position starting January 2018. Since December 2021 he is a member of the CIC faculty.